Mr. James Howard-Tripp reports
STAGEZERO LIFE SCIENCES LTD ANNOUNCES INITIATION OF TRADING UNDER THE STOCK TRADING SYMBOL SZLS
Beginning on June 26, 2019, Stagezero Life Sciences Ltd. (formerly GeneNews Ltd.) will trade under the ticker symbol SZLS. Trading will continue in the company's common shares under the new name, symbol and Cusip number. The company officially changed its name from GeneNews to Stagezero Life Sciences on June 20, 2019.
"We are very pleased to execute this final step in our name change to Stagezero Life Sciences Ltd.," commented James R. Howard-Tripp, chairman and chief executive officer. "We can now focus all of our energies on the multitude of opportunities that are ahead of us, including bringing our multicancer panel, Aristotle, into final validation, as well as ensuring our current and future tests are readily available to patients via telehealth, large health care systems and large employers."
The logistics of the name change with respect to current share certificates will be taken care of in the normal course of business.
About Stagezero Life Sciences Ltd.
Stagezero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Its next-generation test, Aristotle, is a multicancer panel for simultaneously screening for 10 cancers from a single sample of blood, with high sensitivity and specificity for each cancer. Aristotle is built on the company's proven and proprietary Sentinel Principle technology platform, which was validated on 10,000 patients and used to develop the first liquid biopsy for colorectal cancer. Further validation of the Aristotle test is currently under way.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.